Screening for diabetic retinopathy: New methods to come
Sir, Diabetes is a commonly discussed disease condition for its effects on almost each system of human body. The macro as well microvascular complications of diabetes are detrimental for the important organs. Ophthalmological involvement of the disease is of much concern as it can result in blindness. Hence, the search is going on an optimum method for screening of diabetic retinopathy so that early detection of any problem can be diagnosed as well as treated.
Early detection and treatment can halt complications of diabetic retinopathy (DR) to a great extent. A nation-wide drive to screen for DR has already been launched from November 14 th -20 th 2014. Studies were able to demonstrate that early treatment can result in a reduction of the risk of vision loss by 57%. Apart from dilated fundoscopic examination, several other alternatives such as digital nonmydriatic retinal imaging (NMRI) technique has been developed to include a larger number of patients under screening program for DR. However, the sensitivity and specificity of NMRI technique have been found to be around 60% and 70%, respectively. The presence of the cataract in older patients limits its proper practical implications. [1] A pilot study has demonstrated the success of automated DR imaging for screening in Indian population. [2] Recently, a retrospective cohort analysis of 15,015 diabetics underwent a retinal screening and nonmydriatic fundus photography through Intelligent Retinal Imaging System (IRIS). The IRIS computer algorithm-based screening program showed high sensitivity and a low false-negative rate. Further, data are required so that such screening methods become more patient-friendly, cost-effective. Application of this type of algorithm can be pursued for the better understanding of the contribution of teleretinal imaging as well as automated analysis in the case of diabetic patients.
[3]
Data on literature have also showed that reduced visual acuity may predict inaccuracy in image analysis in patients screened for DR by nonmydriatic retinal photography.
[4]
Proper utilization of these techniques needs more information. However, undoubtedly future will provide promising result in this field.
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Paralytic ileus after bilateral intravitreal injection of bevacizumab
Sir, There are few reports of systemic adverse events associated with intravitreal injection of bevacizumab (IVB). Rare systemic events include formed visual hallucinations, [1] erectile dysfunction, [2] and acute decrease in kidney function.
[3] We recently experienced a case of paralytic ileus after bilateral IVB, thus herein report the case.
A 47-year-old male patient was screened for diabetic retinopathy. He was admitted to the department of internal medicine with uncontrolled Type 2 diabetes mellitus. The blood sugar test was 496 mg/dL and hemoglobin A1c was 13.6%. At the initial ophthalmic examination, his corrected visual acuity was 20/40 in the right eye and 20/30 in the left eye. The intraocular pressure was 18 mmHg in the right eye and 19 mmHg in the left eye. Slit lamp examination revealed no abnormal findings in anterior segment while the funduscopic examination showed microaneurysms and dot hemorrhages in four quadrants. Fluorescein angiography revealed the neovascularization with leakage of dye in both eyes. The IVB (1.25 mg/0.05 mL) was done in both eyes in the same day with patient's request of prompt treatment. Panretinal photocoagulation was scheduled in both eyes after 2 days; however, the laser photocoagulation could not be done because of patient's severe abdominal pain with vomiting and abdominal distension.
An erect abdominal X-ray demonstrated excess air and niveau in the intestine [ Fig. 1] . A computed tomography sagittal scan revealed prominent dilated and air-filled images of the intestinal wall, without apparent lesions [ Fig. 2 ]. Paralytic ileus was diagnosed. Paralytic ileus had improved after conservative treatment with ileus tubing, without surgery.
In our case, the patient had no history of gastrointestinal disorder. Matsuyama et al. reported that the plasma vascular endothelial growth factor (VEGF) level decreased markedly as early as 1 day after IVB in patients with diabetic retinopathy.
Thus, it is possible that systemic side effects can develop after IVB as well as after intravenous bevacizumab. Decreased plasma VEGF resulted in the decreased production of nitric oxide, [5] a known vasodilator. Therefore, decreased VEGF
